Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics, received initial funding from Abingworth LLP and Clarus Ventures.
Led by Lewis Cameron, CEO, John Bradshaw, CFO, and Dr Allison Jeynes-Ellis, CMO, Avillion partners with pharmaceutical and biotechnology companies to co-develop and finance latestage therapeutics.
The company will use its clinical development and regulatory expertise to obtain global approvals for a broad range of drugs and biologics.
FinSMEs
28/01/2013